Zepbound tirzepatide

Drug Class

Dual GIP and GLP-1 receptor agonist

Mechanism

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that acts on receptors to decrease calorie intake and reduce body weight by delaying gastric emptying and increasing satiety.

Approved Indication

Chronic weight management in adults with obesity (BMI >=30 kg/m2) or overweight (BMI >=27 kg/m2) with at least one weight-related comorbidity.

What This Means For Patients

Zepbound is once-weekly tirzepatide injection approved specifically for chronic weight management. It acts as a dual GIP/GLP-1 receptor agonist to help regulate appetite and caloric intake. Following approvals by the FDA and China NMPA, it is available for clinical use under special import provisions in the Hainan Boao Lecheng pilot zone.

Regulatory Approvals

• FDA — approved (2023) — label
• NMPA — approved (2024) — source

Pivotal Clinical Evidence

• SURMOUNT-1 — Jastreboff et al., N Engl J Med 2022 (NCT04184622) — DOI

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217820s000lbl.pdf
• https://www.lilly.com/news/media-releases/fda-approves-lillys-zepbound-tirzepatide-for-chronic-weight-management
• http://www.nmpa.gov.cn/